Tracers / [99mTc]HYNIC-MGS5
[99mTc]HYNIC-MGS5
Also written as [Tc-99m]Tc-HYNIC-MGS5
- Radionuclide
- Tc-99m t½ 360.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- HYNIC-conjugated minigastrin analog (CCK2R-targeting peptide)
- Target / mechanism
- Cholecystokinin-2 receptor (CCK2R) PMID 30650563
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >95% | HYNIC-MGS5 | 30650563 2019 Pharmaceuticals (Basel) 99mTc-labeling was performed using a previously described exchange labeling approach with tricine and EDDA |
Need this precursor?We can point you to suppliers for [99mTc]HYNIC-MGS5, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 30650563. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 30650563: 'HYNIC-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (HYNIC-MGS5)'. | Stage 28: added indication(s) oth-radioguided-surgery from consolidated missing-rubric review.